Journal article
Phase II Study of the Novel Peptide-Nucleic Acid OHR118 in the Management of Cancer-Related Anorexia/Cachexia
Abstract
BACKGROUND AND OBJECTIVE: OHR118 represents a new class of immunomodulatory and cytoprotective drugs in managing anorexia cachexia. Previously in patients with advanced HIV-AIDS, increases in appetite, strength, and alertness were noted. The objective was to determine the effect of OHR118 on appetite, early satiety, and nutritional intake in patients with advanced cancer. Secondary end points included changes in performance status, lean muscle …
Authors
Chasen M; Hirschman SZ; Bhargava R
Journal
Journal of the American Medical Directors Association, Vol. 12, No. 1, pp. 62–67
Publisher
Elsevier
Publication Date
1 2011
DOI
10.1016/j.jamda.2010.02.012
ISSN
1525-8610